Silence Therapeutics (SLN) Cash from Operations (2024 - 2026)
Silence Therapeutics (SLN) posted Cash from Operations of 15603000.0 for Q1 2026, up 9.89% sequentially from 17316000.0 in Q4 2025, and down 26.76% YoY from 21304196.01 in Q1 2025.
Silence Therapeutics (SLN) Cash from Operations (2024 - 2026) Analysis & Trends
Silence Therapeutics has reported Cash from Operations for 3 years, with the latest figure at 15603000.0 in Q1 2026.
- Quarterly Cash from Operations fell 26.76% year-over-year to 15603000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 65594000.0 (up 7.36% YoY) and the FY2025 annual result came in at 62300000.0, up 7.89% from the prior year.
- Cash from Operations improved to 15603000.0 in Q1 2026 per SLN's latest filing, from 17316000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 5409000.0 in Q2 2024 and troughed at 27481000.0 in Q4 2024.
- A 3-year average of 16171444.44 and a median of 15603000.0 in 2026 frame the typical range for Cash from Operations.
- The widest YoY moves for Cash from Operations: up 57.5% in 2025, down 302.87% in 2025.
- Over 3 years, Cash from Operations stood at 27481000.0 in 2024, then surged by 36.99% to 17316000.0 in 2025, then climbed by 9.89% to 15603000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 15603000.0, 17316000.0, and 10884000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - | 1.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.50 Mn |
| Jun 30, 2026 | 1.50 Mn |
| Mar 31, 2026 | -15.60 Mn |
| Mar 31, 2026 | -15.60 Mn |
| Dec 31, 2025 | -17.32 Mn |
| Dec 31, 2025 | -17.32 Mn |
| Sep 30, 2025 | -10.88 Mn |
| Sep 30, 2025 | -10.88 Mn |
| Jun 30, 2025 | -21.79 Mn |
| Jun 30, 2025 | -21.79 Mn |
| Mar 31, 2025 | -12.31 Mn |
| Mar 31, 2025 | -12.31 Mn |
| Dec 31, 2024 | -27.48 Mn |
| Dec 31, 2024 | -27.48 Mn |
| Sep 30, 2024 | -25.61 Mn |
| Sep 30, 2024 | -25.61 Mn |
| Jun 30, 2024 | -5.41 Mn |
| Jun 30, 2024 | -5.41 Mn |
| Mar 31, 2024 | -9.14 Mn |
| Mar 31, 2024 | -9.14 Mn |